China has over 100 million diabetics, hopes to expand into international insulin markets

Apr 17, 2014

In a global insulin market of about 14 billion USD, China is number two in the number of patients, and with Takeda’s 6 billion and Eli Lilly’s 3 billion USD fine for concealing cancer risks of their diabetes drug Actos, Chinese companies such as Tonghua Dongbao are moving ahead to capture larger shares of the Chinese and international markets.

China Bio news release, April 17, 2014

This website stores cookies on your computer. These cookies are used to provide a more personalized experience and to track your whereabouts around our website in compliance with the European General Data Protection Regulation. If you decide to to opt-out of any future tracking, a cookie will be setup in your browser to remember this choice for one year.

Accept or Deny